Gut macrobiotic and its metabolic pathways modulate cardiovascular disease
Frontiers in Microbiology · 26.09.2023 · 14
DOI: 10.3389/fmicb.2023.1272479 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 26.09.2023. Verfasst von Junwen Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Affiliated Wenling Hospital of Wenzhou Medical University (The First People's Hospital of Wenling), Zhejiang, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Thousands of microorganisms reside in the human gut, and extensive research has demonstrated the crucial role of the gut microbiota in overall health and maintaining homeostasis. The disruption of microbial populations, known as dysbiosis, can impair the host’s metabolism and contribute to the development of various diseases, including cardiovascular disease (CVD). Furthermore, a growing body of evidence indicates that metabolites produced by the gut microbiota play a significant role in the pathogenesis of cardiovascular disease. These bioactive metabolites, such as short-chain fatty acids (SCFAs), trimethylamine (TMA), trimethylamine N-oxide (TMAO), bile acids (BAs), and lipopolysaccharides (LPS), are implicated in conditions such as hypertension and atherosclerosis. These metabolites impact cardiovascular function through various pathways, such as altering the composition of the gut microbiota and activating specific signaling pathways. Targeting the gut microbiota and their metabolic pathways represents a promising approach for the prevention and treatment of cardiovascular diseases. Intervention strategies, such as probiotic drug delivery and fecal transplantation, can selectively modify the composition of the gut microbiota and enhance its beneficial metabolic functions, ultimately leading to improved cardiovascular outcomes. These interventions hold the potential to reshape the gut microbial community and restore its balance, thereby promoting cardiovascular health. Harnessing the potential of these microbial metabolites through targeted interventions offers a novel avenue for tackling cardiovascular health issues. This manuscript provides an in-depth review of the recent advances in gut microbiota research and its impact on cardiovascular health and offers a promising avenue for tackling cardiovascular health issues through gut microbiome-targeted therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Affiliated Wenling Hospital of Wenzhou Medical University (The First People's Hospital of Wenling), Zhejiang, China.
- College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, Hunan, China.
- Department of Pathology, The First People's Hospital of Foshan, Foshan, Guangdong, China.
- Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, Affiliated First Hospital of Ningbo University, Ningbo, China.
Zitieren
APA
Zhu, J., Lyu, J., Zhao, R., Liu, G., & Wang, S. (2023). Gut macrobiotic and its metabolic pathways modulate cardiovascular disease. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1272479
Vancouver
Zhu J, Lyu J, Zhao R, Liu G, Wang S. Gut macrobiotic and its metabolic pathways modulate cardiovascular disease. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1272479
BibTeX
@article{Zhu2023,
author = {Zhu, Junwen and Lyu, Jin and Zhao, Ruochi and Liu, Gang and Wang, Shuangshuang},
title = {Gut macrobiotic and its metabolic pathways modulate cardiovascular disease},
journal = {Frontiers in Microbiology},
year = {2023},
volume = {14},
doi = {10.3389/fmicb.2023.1272479}
}
EUVIMED